Poractant Alfa Suppliers & Bulk Manufacturers
Available Forms: Intratracheal suspension
Available Strengths: 80 mg/mL
Reference Brands: Curosurf(Eu & US)
Category:
Respiratory Disorder
Poractant Alfa (Curosurf) is a natural surfactant used to treat Respiratory Distress Syndrome (RDS) in preterm infants. Available in the US and EU, it comes in 80 mg/mL strength (120 mg and 240 mg vials) and is trusted for effective neonatal respiratory care in NICUs worldwide.
Poractant Alfa is available in Intratracheal suspension
and strengths such as 80 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Poractant Alfa is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Poractant Alfa can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Poractant Alfa, sold under the brand name Curosurf, is a natural surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants. Derived from porcine lung extract, it contains vital surfactant proteins (SP-B and SP-C) that help reduce surface tension in the lungs and improve oxygenation. Curosurf is administered via intratracheal suspension and is available in 80 mg/mL concentrations in 1.5 mL (120 mg) and 3 mL (240 mg) vials. Widely approved and marketed in both the US and EU, Curosurf is trusted in NICUs globally for its proven efficacy in neonatal respiratory support.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing